Dexcom

Short answer: Sometimes — but it depends on the test, who ran the test, and how you present the results. Doctors will often use at‑home results as screening information or a conversation starter, but many will want confirmation from a CLIA‑certified clinical lab or an in‑office/venous draw before making major diagnoses or changing treatment. What matters Lab accreditation: results from a CLIA‑certified lab (or a major clinical lab network) are much more likely to be accepted. Test type: objective, well‑validated measurements (glucose, HbA1c, lipid panels, basic STI tests done in CLIA labs, blood pressure from validated cuffs, CGM glucose) are treated more seriously than novel biomarkers or low‑sensitivity fingerstick panels. Genetic direct‑to‑consumer results are useful but often need clinical confirmatory testing. Sample method & pre‑analytical quality: venous blood draws are generally more reliable than fingerstick. Improper collection, shipping delays, or interfering substances reduce trustworthiness. Clinical context: doctors weigh your symptoms, history, and physical exam against any at‑home data. If results would change management, they usually confirm them in a clinical lab. How to increase the chance a doctor will accept at‑home results Use services that use CLIA‑certified partner labs and provide full lab reports (not just an app summary). Bring/print the full report showing method, reference ranges, and lab accreditation. Tell your clinician why you tested and how (time, fasting, device used). Be prepared for confirmatory testing. Brands and services doctors commonly accept (and why) LabCorp OnDemand / Quest Diagnostics: major clinical lab networks; CLIA‑certified and widely accepted by clinicians and health systems. Good when you want results that behave like a standard clinic lab. HealthLabs / Any Lab Test Now: provide physician‑ordered tests processed by clinical labs — usually accepted. Everlywell / LetsGetChecked / myLAB Box: consumer kits that route samples to CLIA‑certified partner labs. Convenient and often clinically useful, but many clinicians still request confirmatory venous testing for abnormal or borderline results. Dexcom / FreeStyle Libre (CGMs): validated continuous glucose monitors used in diabetes care and generally accepted by clinicians for glucose trends and management. Omron (home blood pressure monitors): clinically validated home BP devices are commonly accepted for hypertension management. 23andMe / AncestryDNA: useful for genetic clues; physicians typically treat results as preliminary and order clinical genetic testing if important medical decisions depend on them. Bottom line At‑home lab results can be very useful, especially when produced by CLIA‑certified labs or validated devices, but many doctors will want confirmatory testing in a clinical setting before making major diagnostic or treatment decisions. If you want a clinician to take your results seriously, use reputable/CLIA‑certified services, bring detailed reports, and be ready to repeat key tests in‑office if requested.

Mentioned in position 8 of 12

Short answer — several routine blood biomarkers are strongly associated with long-term health and mortality risk. They cluster around metabolic health (glucose/insulin), lipid/atherosclerosis risk, inflammation, kidney/liver function, hematologic status, micronutrients, and a few specialty markers and "biological age" tests. Below I list the most useful markers, why they matter, typical direction you want them to go, which test measures them, and a few services/companies that can run or interpret them. Important disclaimer: this is general information, not medical advice. Discuss abnormal results and treatment decisions with your clinician. Top-priority biomarkers for longevity (what to test and why) Hemoglobin A1c (A1c), fasting glucose, fasting insulin (or HOMA-IR) Why: chronic higher glucose and insulin resistance drive diabetes, vascular disease, dementia. Direction: lower within normal — A1c <5.7% is ideal; fasting glucose <100 mg/dL; lower fasting insulin and HOMA-IR indicate better metabolic health. How to test: standard lab panels. Lipids: LDL-C, non‑HDL, triglycerides, HDL — and better predictors: ApoB and ApoA1 Why: lipid-related atherosclerotic risk is the main driver of premature cardiovascular death. Direction: lower LDL-C/ApoB/non‑HDL; higher HDL (within reason); low triglycerides. ApoB is often a better single-number predictor than LDL-C. How to test: standard lipid panel + ApoB. Lp(a) (lipoprotein(a)) Why: genetically driven risk factor for atherosclerosis; important to know once. Direction: lower is better; elevated Lp(a) increases lifetime CV risk. How to test: single blood test. High-sensitivity CRP (hs‑CRP), and if available IL‑6 or fibrinogen Why: markers of chronic systemic inflammation predict cardiovascular events and mortality. Direction: hs‑CRP <1 mg/L is low-risk; higher indicates increased risk. Kidney function: serum creatinine, eGFR, and cystatin C when available Why: kidney disease strongly increases mortality risk. Direction: higher eGFR / lower creatinine (age-adjusted); cystatin C can detect impairment earlier. Liver enzymes: ALT, AST, GGT Why: fatty liver and liver dysfunction are linked to metabolic disease and mortality. Direction: lower or within normal range; elevated GGT often signals metabolic stress or alcohol use. Complete blood count (CBC) including red cell distribution width (RDW), hemoglobin, hematocrit Why: anemia and elevated RDW correlate with mortality and frailty. Direction: avoid anemia; lower RDW is better. Serum albumin and prealbumin Why: markers of nutrition / physiologic reserve; low albumin predicts worse outcomes. Direction: higher within normal range. Ferritin and iron studies (if iron disorder suspected) Why: both iron deficiency and iron overload have health consequences. Direction: context-dependent — treat deficiency; avoid excess. Vitamin D (25‑OH vitamin D) Why: low vitamin D associates with higher mortality and multiple chronic diseases. Direction: many experts aim for 30–50 ng/mL (discuss with clinician). Homocysteine Why: associated with vascular risk and cognitive decline in some studies. Direction: lower is better; treatable with B vitamins if elevated. Specialty or advanced markers / biological aging tests ApoB/ApoA1 ratio and advanced lipoprotein testing (NMR) Why: refines cardiovascular risk beyond standard lipids. Services: Quest, LabCorp, and specialized labs. Lipoprotein(a) — see above (genetic risk) Cystatin C (more sensitive kidney marker) High-sensitivity troponin (in some research settings) for silent cardiac risk D‑dimer, NT‑proBNP in selected cases (cardiac/clotting risk) Telomere length, epigenetic clocks (DNAm GrimAge, DNAm PhenoAge) Why: attempt to estimate biological age rather than chronological age. Research-useful but clinical utility is still emerging. Providers: TruDiagnostic (epigenetic clock tests), Zymo Research / Chronomics (some services), EpiAging technologies. Expect higher cost and evolving interpretation. Practical prioritization if you want to test only a few things Essentials: A1c (or fasting glucose), fasting lipid panel + ApoB, hs‑CRP, CBC, basic metabolic panel (creatinine/eGFR), ALT/AST, and vitamin D. If you have family history of early heart disease: add Lp(a) and advanced lipid testing. If concerned about biological age or prevention investment: consider epigenetic clock testing via TruDiagnostic or similar. Where to get these tests and interpretation (brands/services) Local clinical labs: Quest Diagnostics and LabCorp — widely available, accepted by clinicians and insurers. Direct-to-consumer / at-home kits: Everlywell, LetsGetChecked — convenient for many standard tests (A1c, lipids, vitamin D, thyroid). Interpretation + coaching platforms: InsideTracker, WellnessFX, and Thorne’s personalized lab services — they provide interpretation, personalized recommendations, and repeat testing plans. Continuous glucose monitoring and metabolic coaching: Abbott FreeStyle Libre or Dexcom + Levels app (Levels provides CGM-based coaching) — useful for understanding glucose spikes in non-diabetics. Epigenetic/biological-age testing: TruDiagnostic — focused on DNAm clocks and provides longitudinal reports; other players include Chronomics and Zymo Research (myDNAge). Specialty / research labs: Mayo Clinic Laboratories for complex panels; Quest/LabCorp also offer advanced tests (ApoB, Lp(a), NMR lipoprofile). How often to test Baseline and then annually for most markers if normal. Every 3–6 months if you’re making an intervention (starting statin, weight loss, diabetes therapy) or if values are abnormal. What actually improves longevity (brief) Lowering long-term exposure to high glucose/insulin, lowering atherogenic lipoproteins (ApoB/LDL), reducing chronic inflammation, preserving kidney and liver function, avoiding anemia and severe micronutrient deficiencies, and maintaining muscle mass and physical fitness. Proven interventions include lifestyle (diet quality, regular physical activity, adequate sleep, smoking cessation), control of blood pressure and lipids (including statins when indicated), and glycemic control in people with diabetes. Work with your clinician for medication decisions. If you want, I can: Suggest a compact “starter panel” tailored to your age/sex/family history. Point to which companies or test kits would be best for a specific marker (e.g., where to get ApoB, Lp(a), epigenetic clock). Explain target ranges in more detail for any one marker. Which would you like next?

Mentioned in position 9 of 14

Short answer: Yes — many at‑home blood tests can be accurate enough for routine screening or monitoring, but accuracy depends on the test type, how the sample is collected and handled, and the lab doing the analysis. For important or unexpected results you should confirm with a clinician and/or a venous blood draw. Key points to know Type of sample matters. Finger‑stick (capillary) or dried blood spot tests are fine for many chemistry and hormone assays (cholesterol, HbA1c, thyroid hormones, many STIs and vitamin D), but some tests (full CBC, detailed coagulation studies, certain immunology panels) need a venous draw for reliable results. Pre‑analytic factors matter a lot. Poor technique, insufficient sample volume, contamination, or delays/extreme temperature during shipping can change results. Test method and lab quality matter. Tests run by CLIA‑certified, accredited labs and validated assays are more trustworthy. FDA clearance or review is an additional reassurance for some kits. Intended use: at‑home kits are good for routine screening, wellness monitoring, and convenience. They are less appropriate for acute symptoms or when immediate clinical decisions are needed. Which home options are generally more reliable Home collection kits from major clinical labs (e.g., Pixel by LabCorp, Quest Diagnostics At‑Home kits): these are run by well‑established clinical labs and usually offer either at‑home phlebotomy or a mailed collection kit processed in their central labs — higher confidence in methods and lab quality. Direct‑to‑consumer companies that partner with reputable labs: Everlywell, LetsGetChecked, Vault Health, Modern Fertility, Thorne. These companies typically use CLIA‑certified labs and provide clear instructions and result reports; some also offer nurse/physician follow‑up. Disease‑specific devices: For example, FDA‑cleared HIV self‑tests (oral swab) and approved home COVID antigen tests have known performance characteristics. For chronic care devices, at‑home glucose meters (Abbott FreeStyle, Contour, Dexcom CGM systems for continuous glucose monitoring) and home INR meters (CoaguChek) have established accuracy standards and clinical use. When to be cautious Complex tests (CBC differentials, many immunology assays, some coagulation panels) and tests used to make urgent clinical decisions are best done in a clinic. Genetic and ancestry tests can be technically accurate for the variants they test, but clinical interpretation may be limited; confirm medically actionable genetic findings with a diagnostic lab and genetic counseling. Home antibody tests (for past infection) and some dried blood spot tests may have lower sensitivity/specificity depending on timing and the assay. How to choose a provider Select kits processed by CLIA‑certified labs and look for lab accreditations (CAP) or FDA clearance where relevant. Read instructions carefully and follow pretest requirements (fasting, timing, warm hands). Prefer services that show the lab name and method, offer follow‑up support (nurse/physician), and let you download the lab report. If results are abnormal or don’t match how you feel, confirm with an in‑person venous draw and discuss with your clinician. Bottom line At‑home blood testing is a convenient and often accurate option for many screening and monitoring needs when you choose reputable providers and follow instructions carefully. For critical diagnoses, complex tests, or surprising results, confirm with a clinician and a traditional venous blood test. If you tell me what specific test(s) you’re considering, I can recommend reliable providers for that test and what to watch for.

Mentioned in position 10 of 11

Short answer: Yes — sometimes. Many doctors will take at‑home lab results seriously, but it depends on the test, how the sample was handled, and who ran the test. What matters Who processed the sample: results from a CLIA‑certified / accredited lab or an FDA‑cleared device are far more credible than results from an unregulated service. Sample type and method: finger‑stick capillary blood or mail‑in saliva can be fine for some analytes (e.g., home glucose, many STI PCR kits) but less reliable for others that require venous blood. Clinical context: screening or trend information is often useful; doctors usually want a confirmatory, clinic‑grade test before making major treatment changes. Examples doctors commonly accept Home glucose meters and continuous glucose monitors (Dexcom, Abbott FreeStyle Libre) — widely used for diabetes care. Home INR monitors (CoaguChek) — accepted for anticoagulation management when used correctly and with documentation. Home blood pressure monitors from validated brands (Omron) — clinicians rely on these for hypertension management when validated models and proper technique are used. Direct‑to‑consumer kits processed by CLIA‑certified labs (Everlywell, LetsGetChecked, Walk-In Lab or services that use Quest Diagnostics / LabCorp laboratories) — many PCPs will accept results from these if the lab is listed and report shows methods/limits. Home COVID or pregnancy tests that are FDA‑authorized (Abbott BinaxNOW, Clearblue, First Response) — commonly accepted. When doctors are cautious Consumer genetic reports (23andMe, AncestryDNA): useful for general info but usually need confirmatory, clinical genetic testing before acting. Tests without lab accreditation, unclear methodology, or poor sample chain‑of‑custody: likely to be questioned. Any abnormal result that would change management usually prompts ordering a confirmatory venous sample at a clinical lab. How to improve acceptance Use companies that send samples to CLIA‑certified labs and show the lab name/CLIA number on the report (Everlywell, LetsGetChecked, or tests routed through Quest/LabCorp). Bring or share the original lab report (not just a screenshot): include units, reference ranges, collection date, and lab accreditation. Tell your clinician how the sample was collected and when. Be ready for them to order a confirmatory test if needed. If you want, tell me: which at‑home test or company you used and the result — I can help judge how a clinician is likely to view it and whether you should expect confirmatory testing.

Mentioned in position 1 of 14

How often you should retest blood biomarkers depends on which tests, your health status, whether you’re on treatment, and any recent changes (symptoms, new meds, lifestyle change). Below is a practical, clinician‑style summary you can use to plan testing plus recommended lab services. General principles Normal + low risk: test less often (months–years). Abnormal, on treatment, or changing therapy: test more often (weeks–months) until stable. New symptoms, pregnancy, starting/stopping meds, or major lifestyle change → test sooner. Coordinate a testing schedule with your clinician so results are interpreted and acted on. Typical frequency by biomarker (common tests) Lipid panel (total cholesterol, LDL, HDL, triglycerides) Healthy, low risk: every 4–6 years (adult screening). On statin or abnormal: 4–12 weeks after initiation or dose change, then every 3–12 months once stable. HbA1c (long‑term glucose control) Diabetes with changes or not at goal: every 3 months. Diabetes stable and at goal: every 6 months. Prediabetes: every 6–12 months. Fasting glucose As needed for screening or with symptoms; often done with HbA1c. Basic metabolic panel / CMP (electrolytes, kidney, liver tests) Healthy: once yearly or with annual physical. On meds affecting kidneys/liver or with abnormal results: more frequently (weeks–months). Liver enzymes (ALT/AST) Baseline, then as clinically indicated; if abnormal or on hepatotoxic meds, repeat in weeks–months. Thyroid stimulating hormone (TSH) Starting or changing levothyroxine/antithyroid drugs: check ~6 weeks after change. Stable on therapy: every 6–12 months. Complete blood count (CBC) Routine healthy adults: annually or as part of workup. If anemia or cytopenia or on meds that affect blood counts: repeat as directed (weeks–months). Vitamin D (25‑OH D) If deficient and repleting: recheck in 8–12 weeks after starting supplementation. If adequate: every 6–12 months if risk factors. High‑sensitivity CRP / inflammatory markers Use case‑specific (cardiac risk tracking or inflammatory disease). Frequency depends on reason — often every 3–12 months if monitoring disease activity. PSA (prostate-specific antigen) Shared decision-making with clinician; if chosen, frequency often every 1–4 years depending on age and risk. Therapeutic drug monitoring / INR / specialty labs Follow specific therapy protocols (e.g., INR testing frequently until stable with warfarin; then interval lengthens). Example schedules Healthy adult, no chronic disease: baseline labs (CBC, CMP, lipid panel, fasting glucose or HbA1c, TSH, vitamin D) then mostly annual or every few years as above. Person with type 2 diabetes: HbA1c every 3 months until controlled, then every 6 months; CMP and lipids per clinician; more frequent if meds change. Starting statin: lipid check 4–12 weeks after start/change, then every 3–12 months. Practical testing options (brands/services) Large clinical labs: Quest Diagnostics, LabCorp — broad test menu, widely accepted by clinicians and insurers. Direct‑to‑consumer/home kits: Everlywell, LetsGetChecked, HealthLabs, or myLAB Box — convenient for basic panels (cholesterol, HbA1c, hormones), but check accuracy and follow up with your clinician for abnormal results. Continuous glucose monitoring (if recommended for diabetes): Dexcom, Abbott FreeStyle Libre. Home INR monitoring for warfarin: CoaguChek. Tips Ask whether fasting is required (many lipid panels can be nonfasting now). Morning draws are preferred for some hormones. Keep copies of past labs to track trends rather than single values. Always discuss abnormal results or changes with your clinician before changing medications. If you tell me which specific biomarkers you’re tracking, whether you have any diagnoses or medications, and your age, I can give a more tailored retesting schedule.

Mentioned in position 7 of 9

Short answer: sometimes — it depends on the test, how it was done, and the company behind it. What matters to doctors Test accuracy and validation: FDA-cleared or EUA tests and those run by CLIA-certified labs are far more likely to be trusted. Clinical context: a home test used for routine monitoring (blood glucose, INR) is treated differently than a one-off screening result for a serious diagnosis. Documentation and chain-of-custody: a clear lab report naming the lab, method, and reference ranges helps; vague consumer app screenshots are less persuasive. Sample quality and timing: poor collection, delayed shipping, or improper handling reduce reliability. Types doctors commonly accept Monitoring devices: glucose meters, CGMs (Dexcom, Abbott FreeStyle Libre) and home INR machines — often used directly in management. At-home lab tests run by reputable clinical labs (Pixel by Labcorp, QuestDirect, Everlywell, LetsGetChecked) — good for screening and often physician-reviewed reports. Rapid antigen COVID tests (FDA-authorized kits like Abbott BinaxNOW) — useful, though PCR confirmation may be requested. Home pregnancy tests — usually accepted, though providers may confirm with lab beta-hCG for unclear cases. When doctors will want confirmation Any result that would lead to a major treatment change (starting/stopping meds, surgery, diagnosis of serious disease). Positive/negative results from lower-quality kits or non-CLIA consumer tests. Genetic/ancestry tests (23andMe, AncestryDNA) — useful for personal info but not diagnostic for most medical decisions; clinical genetic testing is needed for medical action. Recommended brands/services (examples) Pixel by Labcorp and QuestDirect — consumer-ordered tests run by large clinical labs (CLIA-certified). Everlywell and LetsGetChecked — DTC companies that partner with clinical labs and provide physician-reviewed reports. Dexcom and Abbott FreeStyle Libre — clinically used continuous glucose monitors accepted by clinicians. Abbott BinaxNOW — widely used FDA-authorized rapid COVID antigen test. 23andMe — useful for consumer genetic information but not a medical diagnostic (confirm clinically if medically relevant). How to present home results to your doctor Bring the official report (PDF) that shows the lab name, accreditation, method, date, and reference ranges. Explain how and when the sample was collected. Share symptoms and medical history so the doctor can weigh the result in context. Expect they may order a confirmatory test through their lab for anything that would change care. If you want, tell me which at-home test you have and what the result was, and I can tell you how likely a doctor is to accept it and whether confirmatory testing is advisable.

Mentioned in position 1 of 8